Fosamax for Paget's Disease: What Women Need to Know About Off-Label Alendronate

What Is Paget's Disease of Bone, and Why Does It Affect Women Differently?

Paget's disease of bone is a chronic disorder in which the normal cycle of bone resorption and formation breaks down, producing bone that is structurally disorganized, enlarged, and more prone to fracture. It is not the same disease as Paget's disease of the breast. In the skeleton, affected bones remodel at a dramatically accelerated rate, generating mechanically inferior tissue despite increased density on imaging.

Paget's disease affects an estimated 1-3% of adults over age 55 in Western populations, with prevalence rising sharply after age 70. The disease is slightly more common in men overall, but women who develop it tend to be postmenopausal, meaning they already carry a baseline deficit of estrogen-mediated bone protection.

How Menopause Changes the Picture

Estrogen normally restrains osteoclast activity, the cells responsible for bone resorption. After menopause, the loss of estrogen accelerates osteoclast-driven resorption across the whole skeleton. In a woman who also has Paget's disease, this postmenopausal amplification of resorption adds a second layer of skeletal vulnerability on top of the focally chaotic Pagetic lesions. A 2006 study in the Journal of Bone and Mineral Research confirmed that postmenopausal women with Paget's disease have significantly higher rates of fracture at Pagetic sites than men of equivalent disease severity.

This is not a minor distinction. When you and your clinician are deciding whether and how aggressively to treat, your menopausal status matters to that conversation.

Symptoms Women Most Commonly Report

Many women with Paget's disease have no symptoms at all; the diagnosis surfaces incidentally on bloodwork or an X-ray taken for another reason. When symptoms do occur, the most frequent complaints are:

• Deep, aching bone pain, often in the pelvis, spine, or femur
• Bowing of a weight-bearing leg
• Hearing loss when the skull base is involved
• Joint pain from secondary osteoarthritis adjacent to a Pagetic bone
• Headache or facial changes if the skull is affected

Pain that feels like it might be attributed to perimenopause-related musculoskeletal symptoms can occasionally overlap with early Pagetic bone pain. A serum alkaline phosphatase level is a simple first screen.

Is Alendronate Actually Approved for Paget's Disease?

No. This is an off-label use, and that needs to be stated plainly. The FDA-approved indications for alendronate include osteoporosis treatment and prevention in postmenopausal women, glucocorticoid-induced osteoporosis, and osteoporosis in men. Paget's disease of bone does not appear on the approved label for alendronate.

Risedronate (Actonel) and zoledronic acid (Reclast) do carry FDA approval specifically for Paget's disease. Alendronate's use in Paget's disease is supported by clinical trial data and is referenced in specialist practice, but a clinician prescribing it for this purpose is prescribing outside the labeling.

Off-label prescribing is legal, common, and often evidence-based. Understanding the evidence grade behind alendronate for Paget's disease helps you have a more informed conversation with your provider.

The Evidence Behind Alendronate for Paget's Disease

What Randomized Controlled Trials Show

The key clinical evidence for alendronate in Paget's disease comes from trials conducted in the late 1990s and early 2000s. In a landmark multicenter randomized controlled trial, alendronate 40 mg daily for 6 months produced biochemical remission (normalization of serum alkaline phosphatase) in approximately 63% of patients, compared with 17% in the etidronate-treated control group. This trial established that alendronate was meaningfully more potent than the first-generation bisphosphonate etidronate.

A follow-up study confirmed durability: many patients maintained suppressed alkaline phosphatase for 12-24 months after completing the 6-month course.

How Alendronate Compares to Zoledronic Acid

The PRISM trial (Paget's disease Randomized trial of Intensive vs. Symptomatic Management) and the key randomized trial by Reid et al., published in the New England Journal of Medicine in 2005, shifted prescribing practice substantially. In that trial, a single 5 mg intravenous infusion of zoledronic acid produced therapeutic response in 96% of patients at 6 months, compared with 74% for risedronate 30 mg daily for 2 months. Alendronate was not the comparator in that trial, but subsequent observational data and guideline commentary position zoledronic acid above both risedronate and alendronate in efficacy.

The Endocrine Society's 2014 clinical practice guideline on Paget's disease recommends zoledronic acid as the preferred first-line bisphosphonate, while acknowledging that oral bisphosphonates including alendronate remain reasonable alternatives when IV access is problematic, costs are prohibitive, or patient preference favors oral therapy.

GRADE evidence level for alendronate in Paget's disease: Moderate quality (randomized trials with meaningful biochemical endpoints, but limited data on hard clinical outcomes like fracture and deformity prevention).

Why Some Women Still Receive Alendronate for Paget's Disease

Zoledronic acid requires an intravenous infusion, which not every woman can access easily, particularly in rural areas or for patients with limited mobility. The drug also carries a small but real risk of acute-phase reaction (flu-like symptoms for 24-72 hours post-infusion) and requires adequate hydration and normal renal function before administration.

For a woman who is already taking weekly oral alendronate for osteoporosis and is incidentally found to have Paget's disease, her prescribing clinician might reasonably increase the dose to the Pagetic regimen (40 mg daily for 6 months) rather than switch to an infusion. That decision should be made explicitly and documented as off-label.

Dosing: What the Off-Label Regimen Looks Like

The dose of alendronate used in Paget's disease trials is significantly higher than the osteoporosis maintenance dose. The osteoporosis treatment dose is 70 mg once weekly orally. The Paget's disease regimen studied in trials is 40 mg orally once daily for 6 months.

Administration Rules That Are Non-Negotiable

Alendronate must be taken in a very specific way to work at all and to avoid esophageal injury:

• Swallow the tablet with a full 240 mL (8 oz) glass of plain water only, first thing in the morning
• Remain upright (sitting or standing) for at least 30 minutes after taking the tablet
• Eat nothing, drink nothing except plain water, and take no other medications for at least 30 minutes
• Do not lie down until after the first food of the day

These rules apply equally to the osteoporosis dose and the higher Pagetic dose. At 40 mg daily, the total weekly bisphosphonate exposure is substantially higher, so strict adherence to administration technique becomes even more clinically consequential to minimize esophageal irritation.

Duration and Retreatment

The standard course is 6 months. After completing a 6-month course, the decision to retreat depends on whether alkaline phosphatase has normalized and whether it rises again on monitoring. Retreatment is sometimes considered after a minimum interval of 6 months off therapy, but decisions should be individualized.

Monitoring Requirements: What You Actually Need Tracked

The monitoring framework below represents a practical, sex-specific approach that integrates Paget's disease monitoring with the hormonal and metabolic tracking relevant to perimenopausal and postmenopausal women on bisphosphonate therapy.

Before Starting Alendronate for Paget's Disease

Your clinician should establish all of the following at baseline:

• Serum alkaline phosphatase (ALP). The isoenzyme most relevant is bone-specific ALP, though total ALP is the standard clinical tool
• Serum calcium and phosphorus
• 25-hydroxyvitamin D level. The Endocrine Society guideline specifies that vitamin D deficiency should be corrected before starting bisphosphonate therapy for Paget's disease to avoid the risk of hypocalcemia
• Serum creatinine and estimated GFR. Alendronate is not recommended when eGFR is <35 mL/min/1.73 m2
• Bone scan or X-rays to document the extent and location of disease
• Dental assessment, particularly if you have periodontal disease or require dental extractions, because osteonecrosis of the jaw (ONJ) is a rare but serious risk

During the 6-Month Treatment Course

• Serum ALP at 3 months: an early partial response signal
• Serum calcium at 1 month, particularly if your pre-treatment vitamin D was low
• Clinical symptom review at each visit: bone pain, any new neurological symptoms (if skull or spine is involved), hearing

After Completing the Course

• Serum ALP at 6 months, 12 months, and annually thereafter
• A rise in ALP above the upper limit of normal after documented normalization is the signal to reassess the need for retreatment
• Dual-energy X-ray absorptiometry (DXA) scan for bone mineral density should be performed if not done in the past 2 years, because postmenopausal women with Paget's disease are at elevated risk of concurrent osteoporosis

The Postmenopausal Woman: Integrated Monitoring

If you are postmenopausal and receiving alendronate for Paget's disease, your monitoring plan should also include:

• Annual DXA of the lumbar spine and hip, because bisphosphonate therapy for Paget's disease may incidentally treat co-existing osteoporosis
• Hormone status documentation. If you are on menopausal hormone therapy (MHT), your provider should be aware that MHT and bisphosphonates have additive effects on bone mineral density, which is generally favorable but should be tracked
• Thyroid function (TSH) annually, because postmenopausal thyroid disease is common and hyperthyroidism independently accelerates bone loss

Pregnancy, Lactation, and Contraception: A Required Conversation

Alendronate is contraindicated in pregnancy. This needs to be stated directly, not buried.

Pregnancy Category and Human Data

Alendronate was classified as FDA Pregnancy Category C under the former system. Under the current labeling framework, the prescribing information states that alendronate should not be used in pregnancy, as animal studies showed fetal harm at doses producing maternal hypocalcemia, and adequate human data do not exist.

Bisphosphonates bind permanently to bone mineral. Once incorporated, they can be released back into maternal (or fetal) circulation during periods of high bone turnover such as pregnancy and lactation. A 2008 case series and review in Fertility and Sterility documented fetal skeletal abnormalities in animal models and raised concern about inadvertent fetal exposure in women who became pregnant after bisphosphonate use. Human evidence is limited to case reports, and most do not show gross fetal malformation, but the pharmacokinetic concern about long-term bone reservoir and fetal exposure is real.

What This Means If You Could Become Pregnant

Paget's disease most commonly presents after age 55, so the overlap with active fertility is uncommon. But it does occur. Younger women with Paget's disease who are of reproductive age or who are trying to conceive should discuss timing of treatment explicitly with their clinician.

Because bisphosphonates can remain in bone for years after stopping, there is no clean washout period. The American Society for Reproductive Medicine (ASRM) does not have a formal position statement on bisphosphonates and conception, but reproductive endocrinologists generally advise allowing at least 6-12 months between the last bisphosphonate dose and a planned pregnancy attempt, with the understanding that some drug remains in bone indefinitely.

If you are premenopausal and being considered for alendronate for Paget's disease, reliable contraception throughout the treatment course and for at least 6 months afterward is a reasonable precaution.

Lactation

Bisphosphonate transfer into breast milk has not been adequately studied in humans. Given the pharmacokinetic concern about bone-stored drug releasing during lactation, and the absence of safety data, alendronate should not be used in breastfeeding women.

Who This Treatment Is Right For (and Who It Is Not)

Women Who May Be Reasonable Candidates for Alendronate in Paget's Disease

• Postmenopausal women with confirmed Paget's disease who are symptomatic or who have biochemically active disease (elevated ALP greater than twice the upper limit of normal)
• Women for whom IV zoledronic acid is logistically difficult (limited access to infusion centers, rural location, severe needle phobia)
• Women who are already established on weekly oral alendronate for osteoporosis and whose clinician determines a dose escalation to the Pagetic regimen is appropriate
• Women with mild-to-moderate renal impairment (eGFR 35-65 mL/min/1.73 m2) in whom IV zoledronic acid carries greater renal risk, though clinician judgment is required at any level of renal compromise

Women Who Are Not Appropriate Candidates

• Women who are pregnant or breastfeeding (contraindicated)
• Women trying to conceive in the near term
• Women with eGFR <35 mL/min/1.73 m2
• Women with active upper GI disease, esophageal motility disorders, or inability to remain upright for 30 minutes (oral bisphosphonates carry risk of esophageal injury in this group)
• Women with untreated hypocalcemia or severe vitamin D deficiency (treat first, then consider alendronate)
• Women with prior or current osteonecrosis of the jaw

Women with asymptomatic, biochemically mild Paget's disease (ALP less than twice the upper limit of normal, no pain, no involvement of weight-bearing bones or skull) may not need pharmacological treatment at all. The decision to treat should be based on location of disease, symptom burden, and risk of complications, not ALP elevation alone.

Side Effects Specific to Women

The known side effect profile of alendronate applies to all adults, but a few points are particularly relevant for women:

Esophageal and GI Effects

Upper GI symptoms, including heartburn, esophageal irritation, and nausea, are more frequently reported by women in postmarketing data. This may reflect higher rates of pre-existing acid reflux in perimenopausal and postmenopausal women related to hormonal shifts. Strict adherence to the 30-minute upright rule is not optional.

Musculoskeletal Pain

The FDA added a warning in 2008 that severe, sometimes incapacitating bone, joint, and muscle pain may occur with bisphosphonate use, in some cases within days of the first dose. This side effect can be mistaken for worsening Paget's disease or perimenopausal musculoskeletal symptoms. If you develop severe new pain shortly after starting alendronate, contact your provider before assuming it is Pagetic progression.

Atypical Femoral Fracture

Atypical subtrochanteric or diaphyseal femoral fractures are a rare but recognized risk of long-term bisphosphonate use, most commonly reported after more than 5 years of continuous therapy. The 6-month Pagetic regimen carries substantially lower risk than years of osteoporosis maintenance dosing, but any new thigh or groin pain during or after alendronate therapy should be evaluated with X-ray.

Osteonecrosis of the Jaw

ONJ risk is predominantly associated with high-dose IV bisphosphonate therapy in oncology patients, not with the oral doses used in Paget's disease. The risk with oral alendronate at Pagetic doses is low but not zero. The American Association of Oral and Maxillofacial Surgeons estimates the risk of ONJ with oral bisphosphonates at approximately 0.01-0.1%. Elective dental procedures, especially extractions, are best completed before starting therapy.

The Evidence Gap: What We Do Not Know in Women

Women have been included in Paget's disease bisphosphonate trials, but sex-stratified analyses are rarely reported separately. The landmark alendronate RCTs did not publish sex-disaggregated efficacy or safety outcomes. The Endocrine Society's 2014 guideline does not include sex-specific dosing guidance for alendronate in Paget's disease, meaning the 40 mg daily regimen is extrapolated from mixed-sex trial populations to women without direct confirmation that outcomes are equivalent.

Body weight differences, differences in gastric emptying, and post-menopausal changes in renal clearance all theoretically affect bisphosphonate pharmacokinetics in women. This is a real gap. The honest answer is that the current dosing recommendation for women is extrapolated from trials that did not analyze women separately, and this should factor into monitoring decisions.

Questions to Ask Your Provider Before Starting

If your clinician is recommending alendronate specifically for Paget's disease, you have every right to ask:

1. Is there a reason zoledronic acid is not being recommended first?
2. Has my vitamin D been checked and corrected?
3. What ALP target are we aiming for, and how will we know if it is working?
4. Do I need a dental clearance before starting?
5. If I am perimenopausal or still have a uterus, how does this interact with any hormone therapy I am on or considering?